Updated on 27 July 2016
Initial €50,000 Phase 1 grant will fund full feasibility study
Singapore: Symcel, the company behind the cell-based assay tool for real-time cellular bioenergetic measurements, calScreener, has secured Horizon 2020 Phase I funding to prepare the company for the planned commercialisation of its groundbreaking technology. The €50,000 (approx.$54992.50) Phase 1 grant will fund a full feasibility study.
calScreener, the calorimetry based diagnostic tool, addresses the industry's inability to carry out anti microbial susceptibility testing in key clinical fields, including biofilm infection, due to the non existence to date of effective assay and monitoring technologies available to the market. Symcel's novel technology and approach meets these unmet diagnostic needs head on. It provides clinicians dealing with bacterial infections with accurate and fast tests that determine whether an antibiotic should be used in the patient, the type of antibiotic to utilize and the choice of therapy to apply.
Magnus Jannsson, Chief Scientific Officer at Symcel said, "key industry benefits of CalScreener include the fact that it is a high sensitivity, easy to use calorimeter that ensures the fast delivery of reliable information on the type of bacteria involved in infections, enabling a quick choice of individualized patient therapy for hard to diagnose infections. Consequently, once fully commercialized, we believe that our technology is set to have a transformational impact within the healthcare sector."
The feasibility study, which forms Phase I of the Bacterial Analysis and Diagnostics through Growth and Energy in Real-time (BADGER) project, comprises a comprehensive strategic review of Symcel, business model visioning and the development of an effective business plan.
Christer Wallin, CEO of Symcel said, "We are delighted to have been awarded this Phase 1 Horizon 2020 grant and look forward to creating the business plan that will guide our upcoming validation and exploitation efforts. By validating and commercializing CalScreener as a diagnostics tool, the BADGER project will make an important contribution towards fighting antimicrobial resistance in Europe, whilst increasing the level of antibiotic stewardship."
Horizon 2020 is the EU funding programme for research and innovation. It supports SMEs with a new instrument that runs throughout various funded research and innovation fields,enhances EU international research and Third Country participation, attaches high importance to integrate social sciences and humanities encourages to develop a gender dimension in project.